Evaluate and Understand Preferences and Representations in Families of Patients With Regard to High-throughput Sequencing Technology for Diagnostic Purposes

Rare Diseases Clinical Trial

Official title:

Preferences and Representations Concerning High-throughput Sequencing Technologies in Medical Genetics. The Case of Development Anomalies.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02814747
• Other study ID #: OLIVIER-FAIVRE 2014
• Status: Completed
• Phase: N/A
• First received: June 16, 2016
• Last updated: June 23, 2016

Study information

• Verified date: August 2014
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

After the use of DNA chips for diagnostic purposes, high-throughput sequencing (HTS) is transforming the field of developmental diseases, from fundamental research to care. Nonetheless, before HTS can be transferred to everyday clinical practice, in particular for expert diagnosis using exome HTS, it is necessary to anticipate the nature of the information to be given to patients and to parents in order to obtain consent for exome HTS.

The objective in terms of public health is to allow patients with rare diseases to benefit from innovative technologies in optimal conditions of information and accompaniment.

the objectives of this project are to

1. evaluate the preferences of families of patients with development disorders as regard to suspicious and incidental findings from HTS before its introduction for diagnostic purpose,

2. and then, following the exome analyses carried out for diagnostic purposes, describe, analyse and understand the experience, expectations and reactions of families and geneticists concerning the diagnostic trajectory in general and at the time the results of the HTS were announced in particular A methodology that associated quantitative and qualitative approaches was chosen so as to combine the advantages and overcome the shortcomings of each: a quantitative study to investigate a large number of patients, which would ensure a certain representativeness of the population and allow sub-groups analyses to study the upstream phase concerning indications for high-throughput sequencing; and a qualitative study, which though it allows only a small number of patients to be investigated, makes it possible to describe, analyze and understand in depth the complex downstream phenomena of high-throughput sequencing results

Recruitment information / eligibility

• Status: Completed
• Enrollment: 530
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Quantitative study

• INCLUSION CRITERIA

• parents of patients with development anomaly and/or intellectual deficiency with no etiological diagnosis

• parents of patients consulting at the centres of reference in Dijon or Lyon

• parents of patients who have not already benefited from HTS

• parents of patients who are fluent in French

• NON-INCLUSION CRITERIA

• persons without national health insurance cover

• inability to answer the questionnaires

Qualitative study

• INCLUSION CRITERIA

• persons who have provided written informed consent

• parents of patients with a development anomaly

• parents of patients consulting at the centres of reference in Dijon or Lyon

• parents of patients who have already benefited from HTS for diagnostic purposes

• persons fluent in French

• NON-INCLUSION CRITERIA

• persons without national health insurance cover

• cognitive impairment making it impossible for the person to understand the aims of the study

Study Design

Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Rare Diseases

Intervention

Other:
• quantitive study: 500 patients likely to be candidates for HTS

• qualitative study: 30 patients who have benefited from HTS

Locations

Country	Name	City	State
France	CHU Dijon Bourgogne	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Preferences of families of patients concerning the diffusion of incidental results with uncertain interpretation from high-throughput sequencing prior to whole exome analyses		day one
Secondary	Questionnaire on the experiences, expectations and reactions of families and geneticists with regard to the moment the results are announced		day one